Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 1, 2017

Study Completion Date

December 1, 2017

Conditions
ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Interventions
DRUG

CERC-501

Oral dosing of 10 mg CERC-501 daily for 8 weeks

DRUG

placebo

oral dosing of 10 mg placebo daily for 8 weeks

Trial Locations (6)

10029

Icahn School of Medicine at Mount Sinai, New York

27710

Duke University Medical Center, Durham

44106

CaseWestern Reserve University, Cleveland

70030

Baylor College of Medicine, Houston

06510

Yale University, New Haven

46202-l7176

Andrew Goddard, MD, Indianapolis

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Yale University

OTHER

collaborator

Baylor College of Medicine

OTHER

collaborator

Indiana University

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Case Western Reserve University

OTHER

lead

Duke University

OTHER

NCT02218736 - Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a | Biotech Hunter | Biotech Hunter